{"filing":{"accession_number":"0001104659-26-094542","cik":"0001781983","ticker":"APRE","company_name":"Aprea Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"apre-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812x8k.htm"},"events":[{"id":27075,"run_id":24646,"accession_number":"0001104659-26-094542","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Aprea Therapeutics disclosed Q2 2026 financial results, including an operating loss of $4.0 million, net loss of $3.6 million, and cash position of $41.2 million, along with clinical progress updates on lead programs APR-1051 and ATRN-119.","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28444,"accession_number":"0001104659-26-094542","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Aprea's financial results for Q2 2026 and six months ended June 30, 2026, including operating loss of $4.0 million, net loss of $3.6 million, and cash position of $41.2 million. The press release (Exhibit 99.1) is the primary disclosure vehicle for Item 2.02, accompanied by consolidated balance sheets and statements of operations. Material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:36:00.554828+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28445,"accession_number":"0001104659-26-094542","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure announces Aprea's second quarter 2026 financial results, including Q2 operating loss of $4.0 million, net loss of $3.6 million, cash position of $41.2 million, and clinical progress updates on lead programs APR-1051 and ATRN-119. The attached Exhibit 99.1 is a formal earnings release with consolidated financial statements and detailed business updates, which is the hallmark of an earnings_release event. This is material to investors assessing the company's financial condition and clinical development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:36:00.554828+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28444,"accession_number":"0001104659-26-094542","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Aprea's financial results for Q2 2026 and six months ended June 30, 2026, including operating loss of $4.0 million, net loss of $3.6 million, and cash position of $41.2 million. The press release (Exhibit 99.1) is the primary disclosure vehicle for Item 2.02, accompanied by consolidated balance sheets and statements of operations. Material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:36:00.554828+00:00","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-08-12"},{"id":28445,"accession_number":"0001104659-26-094542","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure announces Aprea's second quarter 2026 financial results, including Q2 operating loss of $4.0 million, net loss of $3.6 million, cash position of $41.2 million, and clinical progress updates on lead programs APR-1051 and ATRN-119. The attached Exhibit 99.1 is a formal earnings release with consolidated financial statements and detailed business updates, which is the hallmark of an earnings_release event. This is material to investors assessing the company's financial condition and clinical development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:36:00.554828+00:00","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-08-12"}]}